Lisa A. Jackson, MD, MPH

Jackson_Lisa_A__205x293.jpg

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine  safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

Recent publications

Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, Hammerschlag MR, Jackson LA, Kuo CC, Maass M, Messmer TO, Talkington DF, Tondella ML, Zaki SR. Standardizing chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA), and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis. 2001;33(4):492-503. PubMed

Jackson LA, Falls S, Yu O, George J, Pietrobon PJ, Rubanowice D, Froeschle J. Diphtheria antitoxin levels among children primed with a diphtheria and tetanus toxoids and acellular pertussis vaccine lot with a subpotent diphtheria toxoid component. J Infect Dis. 2001;183(11):1698-700. PubMed

Jackson LA, Grayston JT. Chlamydia pneumoniae (TWAR). In: Schlossberg D, ed. Current Therapy of Infectious Disease, 2nd Ed. St. Louis, Mosby - Year Book Inc., 2001: 481-483.

Jackson LA, Wang SP, Nazar-Stewart V, Grayston JT, Vaughan TL. Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1263-6. PubMed

Pellissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Manag Care. 2000;6(9):1038-44. PubMed

Jackson LA, Keene WE, McAnulty JM, Alexander ER, Diermayer M, Davis MA, Hedberg K, Boase J, Barrett TJ, Samadpour M, Fleming DW. Where's the beef? The role of cross-contamination in 4 chain restaurant-associated outbreaks of Escherichia coli 0157:H7 in the Pacific Northwest. Arch Intern Med. 2000;160(15):2380-5. PubMed

Jackson LA, Cherry JD, Wang SP, Grayston JT. Frequency of serological evidence of bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses. Clin Infect Dis. 2000;31(1):3-6. PubMed

Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis. 2000;181 Suppl (3):S579-81. PubMed

Jackson LA, Campbell LA, Schmidt RA, Kuo C, Cappuccio AL, Lee MJ, Grayston JT. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma. J Infect Dis. 2000;181 Suppl (3):S447-8. PubMed

Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis. 2000;181 Suppl (3):S563-5. PubMed

 

News

Vaccine_trial_registry_story_video_1col.jpg

Vaccine program recruiting volunteers in Seattle area

KPWHRI’s vaccine registry was the first to enroll participants in a clinical trial of a COVID-19 vaccine.

News

Mpox-vaccine_1col.jpg

Clinical trial will evaluate mpox vaccine for adolescents

The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.

Volunteers needed

mRNA-vaccine-story_1col.jpg

Researchers begin trial for mRNA flu vaccine

The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.

Research

Shingles-vaccine_1col.jpg

New study confirms safety of shingles vaccine

KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.

Research

Malaria-vaccine_1col.jpg

Gene-edited malaria vaccine shows promise

Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.

KPWHRI In the Media

Seattle-based clinical trial tweaks mRNA vaccines to fight COVID variants

Seattle NPR affiliate KUOW-FM, April 8, 2021